Supplementary Table 1.

Epidemiologic and Clinical Features of the Enrolled Patients With COVID-19 in This Study

Characteristics	Total (n = 401)	Viral RNA in rectal samples
		Positive (n = 80)	Negative (n = 321)	P value
Age, y, median (IQR)	47 (33–60)	38 (20–54)	49 (3–61)	.0001
Age subgroups, n (%)
Children: 0–17 y	30 (7.5)	17 (56.67)	13 (43.33)	<.0001
Adults: 18 and >18 y	371 (92.5)	63 (16.98)	308 (83.02)	<.0001
Male, n (%)	190 (47.4)	32 (40.0)	158 (49.2)	.176
BMI, median (IQR)	23.1 (20.9–25.3)	21.3 (18.5–23.9)	23.4 (21.4–25.5)	<.0001
Disease severity, n (%)
Mild/moderate	316 (78.8)	69 (86.3)	247 (76.9)	.037
Severe/critical	85 (21.2)	11 (13.7)	74 (23.1)	.037
Initial symptoms, n (%)
Fever	268 (66.8)	50 (62.5)	218 (67.9)	.431
Cough	139 (34.7)	26 (32.5)	113 (35.2)	.747
Expectoration	11 (2.7)	0 (0)	11(3.4)	.131
Headache	12 (3.0)	1 (1.3)	11(3.4)	.473
Myalgia	13 (3.2)	2 (2.5)	11(3.4)	1.00
Chills	3 (0.7)	1 (1.3)	2 (0.6)	.488
Nausea or vomiting	1 (0.2)	1 (0.3)	0 (0)	1
Diarrhea	25 (6.2)	6 (7.5)	19 (5.9)	.61
Coexisting chronic medical conditions, n (%)
Chronic heart disease	8 (2.0)	1 (1.3)	7 (2.2)	1.00
Chronic lung disease	3 (0.7)	0 (0)	3 (0.9)	1.00
Chronic renal disease	6 (1.5)	0 (0)	6 (1.9)	.604
Chronic liver disease	23 (5.7)	1 (1.3)	22 (6.9)	.06
Diabetes	14 (3.5)	0 (0)	14 (4.4)	.082
Hypertension	22 (5.5)	1 (1.3)	21 (6.5)	.095
Cancer	1 (0.2)	0 (0)	1 (0.3)	1.00
Exposure history, n (%)
Wuhan/Hubei	297 (74.1)	49 (61.3)	248 (77.3)	.005
Interval, d, median (IQR)
Onset to admission	3 (1–6)	3 (1–6)	3 (1–6)	.50
Onset to laboratory confirmation	2 (0–4)	1 (0–4)	2 (0–5)	.31
Onset to antiviral treatment	3 (1–6)	5 (2–7)	2 (1–5)	.028

BMI, body mass index; IQR, interquartile range.